Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

DCPH Deciphera Pharmaceuticals

18.500
+0.880+4.99%
Close 09/30 16:00 ET
18.5000.0000.00%
Post Mkt Price 09/30 16:02 ET
High
19.310
Open
17.670
Turnover
25.99M
Low
17.425
Pre Close
17.620
Volume
1.40M
Market Cap
1.24B
P/E(TTM)
Loss
52wk High
37.990
Shares
66.82M
P/E(Static)
Loss
52wk Low
6.510
Float Cap
672.00M
Bid/Ask %
25.00%
Historical High
71.110
Shs Float
36.32M
Volume Ratio
1.60
Historical Low
6.510
Dividend TTM
--
Div Yield TTM
--
P/B
3.05
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
3.85%
Amplitude
10.70%
Avg Price
18.567
Lot Size
1
Float Cap
672.00M
Bid/Ask %
25.00%
Historical High
71.110
Shs Float
36.32M
Volume Ratio
1.60
Historical Low
6.510
Dividend TTM
--
P/B
3.05
Dividend LFY
--
Turnover Ratio
3.85%
Amplitude
10.70%
Avg Price
18.567
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
CEO: Mr. Steven L. Hoerter
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...